All In Biotech

Drug Trial Radar · NCT05476900

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

A Randomized, Open-label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Oct 6, 2022

Primary completion

Mar 14, 2025

Study completion Mar 14, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042 capsules administration for the treatment.

Conditions

  • Autoimmune Hepatitis

Interventions

  • HR19042 CapsulesDrug

    HR19042 Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of biochemical response after 12 weeks of treatment.Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Jiao Tong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.